L-Alaninamide Hydrochloride CAS 33208-99-0 (H-Ala-NH2·HCl) Assay 98.0~102.0% Safinamide Intermediate Factory

L-Alaninamide Hydrochloride (H-Ala-NH2·HCl) (CAS: 33208-99-0) is used as pharmaceutical intermediates. L-Alaninamide Hydrochloride is used for preparation of novel amide derivatives of steroidal[3,2-c]pyrazole compounds with glucocorticoid activity. L-Alaninamide Hydrochloride is an intermediate of Safinamide (CAS: 133865-89-1) and Safinamide Mesylate (CAS: 202825-46-5). Safinamide is a selective and reversible inhibitor of monoamine oxidase B (MAO-B, IC50=98 nM with greater than 100-fold selectivity over MAO-A. Displays anticonvulsant activity and protects against kainate-induced seizures and hippocampal neurodegeneration in rat models. Reduces overactive glutamatergic signaling via use-dependent sodium channel blockade. A novel therapeutic for Parkinson’s disease with multiple modes of action. Effective as an add-on to dopamine agonist therapy in early Parkinson's. Safinamide methanesulfonate was approved in February 2015 by the EMA for the treatment of mid- to late-stage fluctuating Parkinson’s disease. This approval included use of the drug as an add-on therapy for use with Levodopa, either alone or in combination with other existing therapies for Parkinson’s disease. Safinamide methanesulfonate, an oral α-aminoamide originally discovered by Farmitalia Carlo Erba and later developed by Newron/Zambon, functions as a highly selective and reversible inhibitor of MAO-B, leading to increased levels of dopamine and subsequent improvement in the motor symptoms of Parkinson’s disease, side effects that often result from use of other traditional treatments relying on dopamine replacement therapy.